Jérôme H. Kim

Active 1991–2025

Also published as
Jerome H. Kim
130
Papers
21,208
Citations
72
h-index
121
i10-index

Citations

Citations per year for Jérôme H. Kim1986: 1 citations1992: 1 citations1993: 5 citations1994: 5 citations1995: 1 citations1996: 6 citations1997: 1 citations1998: 1 citations1999: 1 citations2000: 1 citations2001: 2 citations2003: 3 citations2004: 4 citations2005: 2 citations2007: 1 citations2009: 11 citations2010: 68 citations2011: 91 citations2012: 139 citations2013: 174 citations2014: 257 citations2015: 221 citations2016: 219 citations2017: 254 citations2018: 185 citations2019: 846 citations2020: 802 citations2021: 859 citations2022: 573 citations2023: 393 citations2024: 653 citations2025: 277 citations2026: 3 citations1987–1991: no citations, so these years are not shown2002: no citations, so this year is not shown2006: no citations, so this year is not shown2008: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,130 citing papers, 30.1% of this breakdownUnited Kingdom: 511 citing papers, 7.2% of this breakdownChina: 314 citing papers, 4.4% of this breakdownCanada: 311 citing papers, 4.4% of this breakdownAustralia: 246 citing papers, 3.5% of this breakdownSouth Africa: 244 citing papers, 3.4% of this breakdownFrance: 219 citing papers, 3.1% of this breakdownGermany: 216 citing papers, 3.1% of this breakdownNetherlands: 205 citing papers, 2.9% of this breakdownItaly: 164 citing papers, 2.3% of this breakdownSwitzerland: 161 citing papers, 2.3% of this breakdownIndia: 156 citing papers, 2.2% of this breakdown
0%30.1%Other 31.1%

Fields

  • Immunology and Microbiology44.2%
  • Medicine33.9%
  • Biochemistry, Genetics and Molecular Biology9.3%
  • Social Sciences3.7%
  • Agricultural and Biological Sciences3.6%
  • Mathematics0.9%
  • Other4.4%

Topics

  • HIV Research and Treatment14.6%
  • Immune Cell Function and Interaction5.8%
  • SARS-CoV-2 and COVID-19 Research5.3%
  • HIV/AIDS Research and Interventions5.1%
  • HIV/AIDS drug development and treatment4%
  • T-cell and B-cell Immunology3%
  • Other62.2%

Coauthors

All papers

Open in search
  1. Vaccine development for emerging infectious diseases

    Authors: , , , - Nature Medicine 2021 cited by 415

  2. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 cited by 3,028

  3. Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Phillip W. Berman, Nicole Frahm, Stephen C. De Rosa, Michael D. Alpert, Nicole L. Yates, Xiaoying Shen, Richard A. Koup, Punnee Pitisuttithum, Jaranit Kaewkungwal, Sorachai Nitayaphan, Supachai Rerks‐Ngarm, Nelson L. Michael, Jérôme H. Kim - New England Journal of Medicine 2012 cited by 1,834

  4. Vaccines and therapeutics for immunocompromised patients with COVID-19

    Authors: , , , , , , , , , , , , , , , , - EClinicalMedicine 2023 cited by 118

  5. The global burden and epidemiology of invasive non-typhoidal Salmonella infections

    Authors: , , , , , , , , - Human Vaccines & Immunotherapeutics 2018 cited by 244

  6. Central Nervous System Viral Invasion and Inflammation During Acute HIV Infection

    Authors: , , , , , , , , , , , , , - The Journal of Infectious Diseases 2012 cited by 533

  7. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2018 cited by 333

  8. Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology

    Authors: , , , , , , , , , , , , , , , , , , , , , - Cell 2015 cited by 371

  9. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2014 cited by 635

  10. COMPASS identifies T-cell subsets correlated with clinical outcomes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Biotechnology 2015 cited by 291

  11. Looking beyond COVID-19 vaccine phase 3 trials

    Authors: , , - Nature Medicine 2021 cited by 633

  12. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection

    Authors: , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2016 cited by 264

  13. Vaccine access, equity and justice: COVID-19 vaccines and vaccination

    Authors: , , , , , , - BMJ Global Health 2023 cited by 81

  14. Comparative safety of mRNA COVID‐19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Medical Virology 2021 cited by 66

  15. Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Georgia D. Tomaras - Science Translational Medicine 2014 cited by 454

  16. The Streptococcus pyogenes vaccine landscape

    Authors: , , , , , - npj Vaccines 2023 cited by 88

  17. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV

    Authors: , , , , , , , , , , , , , - Journal of Clinical Investigation 2019 cited by 84

  18. Factors, enablers and challenges for COVID-19 vaccine development

    Authors: , , , , , , , - BMJ Global Health 2023 cited by 63

  19. Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2014 cited by 408

  20. The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics

    Authors: , , , , , , , , , - Clinical Infectious Diseases 2019 cited by 173

  21. Current approaches to HIV vaccine development: a narrative review

    Authors: , , , - Journal of the International AIDS Society 2021 cited by 90

  22. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2016 cited by 272

  23. Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - PLoS Pathogens 2014 cited by 261

  24. Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , on behalf of the RV254/SEARCH010, RV304/SEARCH013, SEARCH011 study groups - Science Translational Medicine 2020 cited by 108